Replies to post #14781 on Lans Holdings Inc (fka LAHO)

[ApollyonZ]

LAHO! GSCG Partner Magellan..

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149415546

cell therapy market [will] grow..around 36% by 2021,” read the report.

“Stem cells have the remarkable potential to develop into many different cell types in the body during early life and growth,” says the US National Institutes of Health. “In many tissues they serve as a sort of internal repair system, dividing essentially without limit to replenish other cells as long as the person or animal is still alive

Market cap: $2.09 billion; current share price: $24.25
Market cap: $226.15 Million; current share price: $1.83
Market cap: $161.84 million; current share price: $1.47
Market cap: $267.60 million; current share price: $19.10
Market cap: $392.71 million; current share price: $11.25
Market cap: $64.63 million; current share price: $3.43
Market cap: $54.74 million; current share price: $5.78
Market cap: $11.05 million; current share price: $0.31 Million
Market cap: $29.88 million; current share price: $2.75
Market cap: $28.40 million; current share price: $1.30

https://investingnews.com/daily/life-science-investing/genetics-investing/top-stem-cell-nasdaq/

Global Stem Cells Group Announces Opening of Two New Stem Cell Centers

..This brings the total number of global Stem Cell centers to 36 worldwide in 27 countries.
..The new clinic in Valencia will be the group's third operation in Spain and the fourth in Europe.

https://www.nasdaq.com/press-release/laho-global-stem-cells-group-announces-opening-of-two-new-stem-cell-centers-20190612-00503

Cellgenic..regenerative medicine and cellular therapies since 2005..


UNITED STATES STEM CELL THERAPY
More than a Decade of Stem Cell Therapy Experience

Safety along with the highest standards of medical ethics define the Cellgenics system.
We do not take stem cell treatments lightly. Our medical team adheres strictly to our inclusion and exclusion criteria. This leads to a higher efficacy rate because we are aware that not all conditions can be treated successfully with fresh autologous stem cells.

Our therapeutic protocols are designed and tailored for each patient, this means we have different systems in place for the isolation and delivery of the stem cells.
The Cellgenic sytem differs from other stem cell therapy facilities because:

Proprietary protocols have been developed by our faculty and implemented by hundreds of physicians around the world
There is a high rate of therapy success
An ethics committee has approved ongoing clinical trials

..Patients Treatment
+2000

Improvement and satisfaction
95%

Medical cases done
5000

http://cellgenic.com/our-story/#
http://cellgenic.com/articles/